Sort   by:  
 Page size 
TranscriptomicsGenome-wide DNA copy number predictors of lapatinib sensitivity in tumour-derived cell lines
A common aim of pharmacogenomic studies that employ genome-wide assays on panels of cancers is the unbiased discovery of genomic alterations that are associated with clinical outcome and drug response. Previous investigations of lapatinib, a selective dual-kinase inhibitor of EGFR and HER2 tyrosine...
ORGANISM(S): Homo sapiens 
2008-03-10 | E-GEOD-9585 | biostudies-arrayexpress
TranscriptomicsA comparison of DNA copy number profiling platforms using a panel of melanoma cell lines
The accurate mapping of recurring DNA copy number aberrations (CNAs), a hallmark feature of the cancer genome, has facilitated the discovery of tumor suppressor genes and oncogenes. Microarray-based assays designed to detect these chromosomal copy number alterations on a genome-wide and high-resolu...
ORGANISM(S): Homo sapiens 
2010-05-26 | E-GEOD-7822 | biostudies-arrayexpress
GenomicsEGAD00000000119
Genotypes from cell lines derived from breast carcinoma tissue
EGAD00000000119 | EGA
GenomicsAssessment of genomic copy number alterations in breast cancer
The aim of this study was to assess genomic copy number alterations in a panel of breast cancer cell lines. These data were used to identify common aberrations associated with breast cancer, and also to identify aberrations associated with response to therapeutic compounds.
EGAS00000000059 | EGA
GenomicsBreast Cancer Cell Line Data Access Committee
Access to data is available by emailing application to the data access committee and will be granted to qualified investigators for appropriate use.
EGAC00000000015 | EGA
ProteomicsDefining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction
Increasing evidence indicates CD4+ T cells can recognize cancer-specific antigens and control tumor growth. However, it remains difficult to predict the antigens that will be presented by human leukocyte antigen class II molecules (HLA-II) - hindering efforts to optimally target them therapeutically...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2019-06-18 | MSV000083991 | MassIVE
Sort   by:  
 Page size